Current Treatment Options in Oncology

, Volume 7, Issue 4, pp 320–325 | Cite as

Reoperation for adrenocortical neoplasms

  • James A. Lee
  • Quan-Yang Duh
Article
  • 24 Downloads

Opinion statement

Adrenocortical cancer is a highly lethal malignancy. Surgical resection remains the only potential modality for cure or appreciable disease-free intervals. Even with radical resection, most patients will recur or have metastatic disease. For these patients, surgical re-resection of local recurrence and metastases is the best chance of controlling disease and prolonging survival. Patients with widely metastatic disease or those with tumors not amenable to re-resection may benefit from tumor debulking to help control symptoms associated with oversecretion syndromes. No currently available regimen of chemotherapy, including mitotane, and/or radiotherapy achieves significant cure or response rates. Multiple promising treatments such as radiofrequency ablation, tyrosine kinase inhibitors, and competitive inhibitors of multidrug resistance gene products are in preclinical trials and may improve patient outcomes.

Keywords

Gossypol Radiofrequency Ablation Adrenocortical Carcinoma Mitotane Adrenocortical Neoplasm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Icard P, Louvel A, Chapuis Y: Survival rates and prognostic factors in adrenocortical carcinoma. World J Surg 1992, 16:753–758.PubMedCrossRefGoogle Scholar
  2. 2.
    Jensen JC, Pass HI, Sindelar WF, Norton JA: Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg 1991, 126:457–461.PubMedGoogle Scholar
  3. 3.
    Schulick RD, Brennan MF: Adrenocortical carcinoma. World J Urol 1999, 17:26–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Brennan MF: Adrenocortical carcinoma. CA Cancer J Clin 1987, 37:348–365.PubMedCrossRefGoogle Scholar
  5. 5.
    Wooten MD, King DK: Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993, 72:3145–3155.PubMedCrossRefGoogle Scholar
  6. 6.
    Dackiw AP, Lee JE, Gagel RF, Evans DB: Adrenal cortical carcinoma. World J Surg 2001, 25:914–926.PubMedCrossRefGoogle Scholar
  7. 7.
    Icard P, Chapuis Y, Andreassian B, et al.: Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992, 112:972–979; discussion 979-980.PubMedGoogle Scholar
  8. 8.
    Ng L, Libertino JM: Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003, 169:5–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Icard P, Goudet P, Charpenay C, et al.: Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2003, 25:891–897.CrossRefGoogle Scholar
  10. 10.
    Vassilopoulou-Sellin R, Schultz PN: Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001, 92:1113–1121.PubMedCrossRefGoogle Scholar
  11. 11.
    Pommier RF, Brennan MF: An eleven-year experience with adrenocortical carcinoma. Surgery 1992, 112:963–970; discussion 961-970.PubMedGoogle Scholar
  12. 12.
    Venkatesh S, Hickey RC, Sellin RV, et al.: Adrenal cortical carcinoma. Cancer 1989, 64:765–769.PubMedCrossRefGoogle Scholar
  13. 13.
    Crucitti F, Bellantone R, Ferrante A, et al.: The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multi-institutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996, 119:161–170.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohn K, Gottesman L, Brennan M: Adrenocortical carcinoma. Surgery 1986, 100:1170–1177.PubMedGoogle Scholar
  15. 15.
    Tauchmanova L, Colao A, Marzano LA, et al.: Andrenocortical carcinomas: twelve-year prospective experience. World J Surg 2004, 28:896–903.PubMedCrossRefGoogle Scholar
  16. 16.
    Bellantone R, Ferrante A, Boscherini M, et al.: Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997, 122:1212–1218. Large series and excellent review of the literature.PubMedCrossRefGoogle Scholar
  17. 17.
    Schulick RD, Brennan MF: Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999, 6:719–726. One of the largest published series and an excellent review of the literature.PubMedCrossRefGoogle Scholar
  18. 18.
    Dickstein G, Shechner C, Arad E, et al.: Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma. J Clin Endocrinol Metab 1998, 83:3100–3103.PubMedCrossRefGoogle Scholar
  19. 19.
    Luton JP, Cerdas S, Billaud L, et al.: Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990, 322:1195–1201.PubMedCrossRefGoogle Scholar
  20. 20.
    Bukowski RM, Wolfe M, Levine HS, et al.: Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 1993, 11:161–165.PubMedGoogle Scholar
  21. 21.
    Williamson SK, Lew D, Miller GJ, et al.: Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group study. Cancer 2000, 88:1159–1165.PubMedCrossRefGoogle Scholar
  22. 22.
    Flack MR, Pyle RG, Mullen NM, et al.: Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 1993, 76:1019–1024.PubMedCrossRefGoogle Scholar
  23. 23.
    Berruti A, Terzolo M, Pia A, et al.: Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998, 83:2194–2200.PubMedCrossRefGoogle Scholar
  24. 24.
    Bonacci R, Gigliotti A, Baudin E, et al.: Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM. Br J Cancer 1998, 78:546–549.PubMedGoogle Scholar
  25. 25.
    Haak HR, Hermans J, van de Velde CJ, et al.: Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994, 69:947–951.PubMedGoogle Scholar
  26. 26.
    Kopf D, Goretzki PE, Lehnert H: Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 2001, 127:143–155.PubMedCrossRefGoogle Scholar
  27. 27.
    Abraham J, Bakke S, Rutt A, et al.: A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002, 94:2333–2343.PubMedCrossRefGoogle Scholar
  28. 28.
    Khan TS, Sundin A, Juhlin C, et al.: Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. Med Oncol 2004, 21:167–177.PubMedCrossRefGoogle Scholar
  29. 29.
    Khan TS, Imam H, Juhlin C, et al.: Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000, 11:1281–1287.PubMedCrossRefGoogle Scholar
  30. 30.
    Curley SA, Izzo F, Ellis LM, et al.: Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000, 232:381–391.PubMedCrossRefGoogle Scholar
  31. 31.
    Mayo-Smith WW, Dupuy DE: Adrenal neoplasms: CT-guided radiofrequency ablation--preliminary results. Radiology 2004, 231:225–230.PubMedCrossRefGoogle Scholar
  32. 32.
    Wood BJ, Abraham J, Hvizda JL, et al.: Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003, 97:554–560. A good review of an emerging treatment for ACC.PubMedCrossRefGoogle Scholar
  33. 33.
    Rhim H, Dodd GD 3rd, Chintapalli KN, et al.: Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics 2004, 24:41–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Percarpio B, Knowlton AH: Radiation therapy of adrenal cortical carcinoma. Acta Radiol Ther Phys Biol 1976, 15:288–292.PubMedGoogle Scholar
  35. 35.
    Kirschner LS: Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 2006, 91:14–21.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • James A. Lee
  • Quan-Yang Duh
    • 1
  1. 1.San Francisco Medical Center, Department of SurgeryUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations